Abstract: Alpelisib (BYL719) is an orally bioavailable, α-selective phosphatidylinositol 3-kinase (PI3K) inhibitor originally developed for oncology but recently repurposed as a targeted therapy for the PIK3CA-Related Overgrowth Spectrum (PROS). PROS encompasses a heterogeneous group of rare disorders driven by postzygotic, somatic gain-of-function mutations in the PIK3CA gene, leading to hyperactivation of the PI3K/AKT/mTOR pathway. Clinical trials and real-world data have demonstrated that alpelisib provides substantial clinical and radiological improvements in PROS patients, effectively reducing vascular malformations and tissue overgrowth. These outcomes led to its approval by the United States Food and Drug Administration (FDA) for PROS. However, the clinical utility of alpelisib is limited by on-target toxicities, most notably hyperglycemia, as well as concerns regarding growth delays in pediatric populations at higher doses. This review synthesizes the pharmacological activity, molecular mechanism of action, structure-activity relationship, current limitations, and future perspectives of alpelisib in the context of PROS, highlighting the ongoing development of mutant-selective inhibitors and novel drug delivery systems.
1. Introduction
The PIK3CA-Related Overgrowth Spectrum (PROS) represents a group of rare, sporadic disorders characterized by the congenital or early-childhood onset of vascular malformations and the asymmetric overgrowth of various tissues [2]. PROS includes several distinct but overlapping clinical phenotypes, such as CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal and spinal anomalies), megalencephaly-capillary malformation (MCAP), and fibroadipose vascular anomaly (FAVA) [2] [3]. The underlying molecular etiology of PROS is driven by postzygotic, somatic activating mutations in the PIK3CA gene, which encodes the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K) [2].
Historically, the management of PROS relied on symptom-directed interventions such as debulking surgery, sclerotherapy, and laser therapy, which are associated with high recurrence rates and functional complications [2]. The discovery of the genetic basis of PROS has shifted the treatment paradigm toward precision medicine. Alpelisib (BYL719), a targeted PI3Kα inhibitor initially approved for PIK3CA-mutated breast cancer, has emerged as a transformative systemic therapy for PROS, directly addressing the root molecular cause of the disease [1] [2].
2. Pharmacological Activity
Alpelisib has demonstrated robust pharmacological activity in both preclinical models and clinical settings for PROS. In preclinical studies using human umbilical vein endothelial cells (HUVECs) expressing PIK3CA mutations, alpelisib successfully reversed abnormal AKT phosphorylation, restored normal cell morphology, and normalized extracellular fibronectin levels [1] [2]. Furthermore, it improved vascular morphogenesis and survival in in vivo mouse models of PROS [1].
Clinically, alpelisib has shown remarkable efficacy. In an early study of 19 patients with various PROS disorders, alpelisib treatment led to substantial clinical improvement and radiological responses in all patients, ameliorating severe symptoms such as intractable vascular tumors, congestive heart failure, hemihypertrophy, gastrointestinal bleeding, and cognitive impairment [2] [3]. The pivotal EPIK-P1 clinical trial (NCT04285723) reported a decrease in target lesion volume in 74.2% of PROS patients treated with alpelisib for 6 months, achieving a mean volume reduction of 13.7%. This significant efficacy led to the FDA approval of alpelisib for PROS [1]. In adults, the approved dose is 250 mg/day, while children have shown excellent tolerance at 50 mg/day in early compassionate use [3]. Notably, the subsequent EPIK-P2 trial did not reach its anticipated 20% reduction in lesion volume, which was likely attributed to the administration of a reduced dose (125 mg) in the adult cohort [1].
3. Molecular Mechanism of Action
The PIK3CA gene encodes the α isoform of the p110 catalytic subunit of PI3K (PI3Kα). In PROS, somatic mutations frequently occur in hotspot regions, such as E542K and E545K in the helical domain, and H1047R and H1047L in the kinase domain [2] [10]. These gain-of-function mutations cause hyperactivation of the PI3K signaling pathway. Normally, class I PI3Ks catalyze the phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), which recruits and activates downstream effector proteins, most notably the AKT and mTOR kinases, driving cellular proliferation, survival, and angiogenesis [2].
Alpelisib is an orally bioavailable, competitive, and highly selective inhibitor of PI3Kα [1] [7]. Belonging to the 2-aminothiazole family, alpelisib functions as an orthosteric inhibitor that blocks the catalytic activity of the enzyme by binding directly to the ATP-binding site of the p110α subunit [6]. By selectively inhibiting PI3Kα, alpelisib directly counteracts the hyperactive signaling induced by PIK3CA mutations, thereby downregulating the downstream AKT/mTOR axis and halting the abnormal growth of affected tissues [2].
4. Structure-Activity Relationship (SAR)
The high selectivity of alpelisib for the PI3Kα isoform over other class I PI3K isoforms (β, γ, and δ) is dictated by specific structural interactions within the ATP-binding pocket of the kinase domain. Crystallographic studies (e.g., PDB ID 4JPS) reveal that alpelisib makes extensive contacts with the P-loop and the hinge region of PI3Kα [13].
While the ATP binding site is highly conserved among PI3K isoforms, isoform specificity is achieved through interactions with non-conserved residues in the hinge region. A critical determinant of alpelisib's selectivity is the residue Q859 in PI3Kα, which forms dual hydrogen bonds with the drug molecule. In other isoforms, this residue is replaced by shorter amino acids (e.g., D856 in PI3Kβ and N836 in PI3Kδ) that cannot establish these stabilizing hydrogen bonds [13]. Additionally, the residue R852 in PI3Kα forms a salt bridge with E798 in the N-lobe of the kinase domain, further defining the unique architecture of the binding pocket that accommodates alpelisib [13].
5. Current Limitations
Despite its efficacy, the clinical use of alpelisib is constrained by significant adverse events (AEs), primarily driven by the on-target inhibition of wild-type PI3Kα, which plays a crucial role in glucose homeostasis [1]. Hyperglycemia is the most frequent AE, affecting approximately 60-64% of treated patients, and often requires dose interruptions or the concomitant use of antidiabetic medications like metformin [1] [5] [12]. Other common toxicities include rash, diarrhea, nausea, decreased appetite, and aphthous ulcers [1] [12].
In the pediatric PROS population, long-term safety remains a critical concern. Recent retrospective studies have reported growth restriction and growth delay in up to 16.7% of pediatric patients receiving alpelisib. This complication appears to be dose-dependent, occurring predominantly in young children (under 10 years of age) receiving high weight-adjusted doses (3.6–4.8 mg/kg/day) [1]. Furthermore, as with many targeted kinase inhibitors, there is a risk of acquired resistance through the activation of compensatory signaling pathways or secondary mutations, which may eventually limit the drug's long-term efficacy [6].
6. Future Perspectives
The future management of PROS aims to optimize the therapeutic index of PI3K pathway inhibition. Ongoing clinical trials, such as the EPIK-L1 phase II/III trial (NCT05948943) and the SESAM study, are actively evaluating alpelisib in specific PROS subtypes like lymphatic malformations and MCAP, respectively [1]. To mitigate pediatric growth delays, establishing optimal weight-adjusted dosing regimens based on rigorous pharmacokinetic data is essential [1].
To overcome the metabolic toxicities associated with wild-type PI3Kα inhibition, next-generation mutant-selective PI3Kα inhibitors are currently in development. Compounds such as RLY-2608, STX-478, and LOXO-783 are designed to selectively target mutant PI3Kα (e.g., H1047R or E545K) while sparing the wild-type enzyme. Early data suggest these agents can maintain potent anti-tumor and anti-overgrowth activity without inducing severe hyperglycemia [10] [6]. Additionally, novel drug delivery systems, including transdermal microneedle patches and targeted nanoparticles, are being explored to enhance local drug concentrations in vascular malformations while minimizing systemic exposure and off-target toxicity [1].
